{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:45Z","timestamp":1794047445125,"version":"4.8.0"},"reference-count":44,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Haploidentical donors offer a potentially readily available donor, especially for non-White patients, for hematopoietic cell transplantation (HCT). In this North American collaboration, we retrospectively analyzed outcomes of first HCT using haploidentical donor and post-transplantation cyclophosphamide (PTCy) in myelodysplastic syndrome\/myeloproliferative neoplasm (MDS\/MPN) overlap neoplasms (MDS\/MPN). We included 120 consecutive patients who underwent HCT using a haploidentical donor for MDS\/MPN across 15 centers. Median age was 62.5 years and 38% were of non-White\/Caucasian ethnicity. The median follow-up was 2.4 years. Graft failure was reported in seven of 120 (6%) patients. At 3 years, nonrelapse mortality (NRM) was 25% (95% confidence interval [CI]: 17-34), relapse 27% (95% CI: 18-36), grade 3-4 acute graftversus- host disease 12% (95% CI: 6-18), chronic graft-versus-host disease requiring systemic immunosuppression 14% (95% CI: 7-20), progression-free survival (PFS) 48% (95% CI: 39-59), and overall survival (OS) 56% (95% CI: 47-67). On multivariable analysis, NRM was statistically significantly associated with advancing age at HCT (per decade increment, subdistribution hazard ratio [sdHR] =3.28; 95% CI: 1.30-8.25); relapse with the presence of mutation in EZH2\/RUNX1\/SETBP1 (sdHR=2.61; 95% CI: 1.06-6.44); PFS with advancing age at HCT (per decade increment, HR=1.98, 95% CI: 1.13-3.45); and OS with advancing age at HCT (per decade increment, HR=2.01; 95% CI: 1.11-3.63) and splenomegaly at HCT\/prior splenectomy (HR=2.20; 95% CI: 1.04-4.65). Haploidentical donors are a viable option for HCT in MDS\/MPN, especially for those disproportionately represented in the unrelated donor registry. Hence, donor mismatch should not preclude HCT for patients with MDS\/MPN, an otherwise incurable malignancy. In addition to patient age, disease-related factors including splenomegaly and high-risk mutations dominate outcomes following HCT.<\/jats:p>","DOI":"10.3324\/haematol.2023.283426","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T02:56:01Z","timestamp":1688612161000},"page":"3321-3332","source":"Crossref","is-referenced-by-count":14,"title":["Haploidentical donor hematopoietic cell transplantation for myelodysplastic\/myeloproliferative overlap neoplasms: results from a North American collaboration"],"prefix":"10.3324","volume":"108","author":[{"given":"Tania","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Ling","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Elmariah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Karantanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz P.","family":"Gondek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Keyzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameem","family":"Abedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan VG","family":"Nadiminti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon R","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Varadhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Otoukesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"54918","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: integrating morphological, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"54919","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"54920","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"54921","doi-asserted-by":"crossref","unstructured":"Itonaga H, Ota S, Ikeda T. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan. Leuk Res. 2018; 75:50-57.","DOI":"10.1016\/j.leukres.2018.11.003"},{"key":"54922","doi-asserted-by":"crossref","unstructured":"Park S, Labopin M, Yakoub-Agha I. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol. 2013; 90(5):355-364.","DOI":"10.1111\/ejh.12073"},{"key":"54923","doi-asserted-by":"crossref","unstructured":"Robin M, de Wreede LC, Padron E. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood. 2022; 140(12):1408-1418.","DOI":"10.1182\/blood.2021015173"},{"key":"54924","doi-asserted-by":"crossref","unstructured":"Sharma P, Shinde SS, Damlaj M. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome\/myeloproliferative neoplasm (MDS\/MPN) overlap syndromes. Leuk Lymphoma. 2017; 58(4):872-881.","DOI":"10.1080\/10428194.2016.1217529"},{"key":"54925","doi-asserted-by":"crossref","unstructured":"Ambinder A, Jain T, Tsai HL, Horowitz MM, Jones RJ, Varadhan R. HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. Blood Adv. 2022; 6(14):4335-4346.","DOI":"10.1182\/bloodadvances.2022007741"},{"key":"54926","doi-asserted-by":"crossref","unstructured":"Kunte S, Rybicki L, Viswabandya A. Allogeneic blood or marrow transplantation with haploidentical donor and posttransplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2022; 36(3):856-864.","DOI":"10.1038\/s41375-021-01449-1"},{"key":"54927","doi-asserted-by":"crossref","unstructured":"Luznik L, O'Donnell PV, Symons HJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14(6):641-650.","DOI":"10.1016\/j.bbmt.2008.03.005"},{"key":"54928","doi-asserted-by":"crossref","unstructured":"Webster JA, Luznik L, Tsai HL. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Adv. 2020; 4(20):5078-5088.","DOI":"10.1182\/bloodadvances.2020002945"},{"key":"54929","doi-asserted-by":"crossref","unstructured":"Karantanos T, Tsai HL, Gondek LP. Genomic landscape of myelodysplastic\/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leuk Lymphoma. 2022; 63(8):1942-1948.","DOI":"10.1080\/10428194.2022.2057488"},{"key":"54930","doi-asserted-by":"crossref","unstructured":"Mei M, Pillai R, Kim S. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023; 108(1):150-160.","DOI":"10.3324\/haematol.2021.280203"},{"key":"54931","doi-asserted-by":"crossref","unstructured":"Palomo L, Meggendorfer M, Hutter S. Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms. Blood. 2020; 136(16):1851-1862.","DOI":"10.1182\/blood.2019004229"},{"key":"54932","doi-asserted-by":"crossref","unstructured":"Karantanos T, Gondek LP, Varadhan R. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes. Br J Haematol. 2021; 193(6):1142-1150.","DOI":"10.1111\/bjh.17534"},{"key":"54933","doi-asserted-by":"crossref","unstructured":"Elena C, Galli A, Such E. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016; 128(10):1408-1417.","DOI":"10.1182\/blood-2016-05-714030"},{"key":"54934","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Tuechler H, Schanz J. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.","DOI":"10.1182\/blood-2012-03-420489"},{"key":"54935","doi-asserted-by":"crossref","unstructured":"Savona MR, Malcovati L, Komrokji R. An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults. Blood. 2015; 125(12):1857-1865.","DOI":"10.1182\/blood-2014-10-607341"},{"key":"54936","doi-asserted-by":"crossref","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021; 27(8):642-649.","DOI":"10.1016\/j.jtct.2021.04.007"},{"key":"54937","doi-asserted-by":"crossref","unstructured":"Lowsky R, Messner H. Mechanisms and treatment of graft failure. 2015;944-958.","DOI":"10.1002\/9781118416426.ch77"},{"key":"54938","unstructured":"Przepiorka D, Weisdorf D, Martin P. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-828."},{"key":"54939","doi-asserted-by":"crossref","unstructured":"Rowlings PA, Przepiorka D, Klein JP. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997; 97(4):855-864.","DOI":"10.1046\/j.1365-2141.1997.1112925.x"},{"key":"54940","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Vallapureddy R, Lasho TL. EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. Blood Cancer J. 2018; 8(1):12.","DOI":"10.1038\/s41408-017-0045-4"},{"key":"54941","doi-asserted-by":"crossref","unstructured":"Thota S, Viny AD, Makishima H. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood. 2014; 124(11):1790-1798.","DOI":"10.1182\/blood-2014-04-567057"},{"key":"54942","doi-asserted-by":"crossref","unstructured":"Tsai SC, Shih LY, Liang ST. Biological activities of RUNX1 mutants predict secondary acute leukemia transformation from chronic myelomonocytic leukemia and myelodysplastic syndromes. Clin Cancer Res. 2015; 21(15):3541-3551.","DOI":"10.1158\/1078-0432.CCR-14-2203"},{"key":"54943","doi-asserted-by":"crossref","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16:1141-1154.","DOI":"10.1214\/aos\/1176350951"},{"key":"54944","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life tables (with discussion). J R Statist Soc B. 1972; 34(2):187-220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"54945","doi-asserted-by":"crossref","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc. 1999; 94:496-509.","DOI":"10.1080\/01621459.1999.10474144"},{"key":"54946","doi-asserted-by":"crossref","unstructured":"Rollison DE, Howlader N, Smith MT. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1):45-52.","DOI":"10.1182\/blood-2008-01-134858"},{"key":"54947","doi-asserted-by":"crossref","unstructured":"Kurosawa S, Shimomura Y, Tachibana T. Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic\/myeloproliferative neoplasms-unclassifiable: a retrospective nationwide study of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020; 26(9):1607-1611.","DOI":"10.1016\/j.bbmt.2020.05.013"},{"key":"54948","doi-asserted-by":"crossref","unstructured":"Jain T, Tsai HL, DeZern AE. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis. Transplant Cell Ther. 2022; 28(5):259.","DOI":"10.1016\/j.jtct.2022.02.004"},{"key":"54949","doi-asserted-by":"crossref","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-798.","DOI":"10.1056\/NEJMoa1110556"},{"key":"54950","doi-asserted-by":"crossref","unstructured":"Harrison CN, Schaap N, Vannucchi AM. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017; 4(7):e317-e324.","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"54951","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa RA, Gotlib J. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807.","DOI":"10.1056\/NEJMoa1110557"},{"key":"54952","doi-asserted-by":"crossref","unstructured":"Padron E, Dezern A, Andrade-Campos M. A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML). Clin Cancer Res. 2016; 22(15):3746-3754.","DOI":"10.1158\/1078-0432.CCR-15-2781"},{"key":"54953","doi-asserted-by":"crossref","unstructured":"Padron E, Painter JS, Kunigal S. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013; 121(25):5068-5077.","DOI":"10.1182\/blood-2012-10-460170"},{"key":"54954","doi-asserted-by":"crossref","unstructured":"Sanber K, Ye K, Tsai HL. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. Leuk Lymphoma. 2023; 64(4):846-855.","DOI":"10.1080\/10428194.2023.2173523"},{"key":"54955","doi-asserted-by":"crossref","unstructured":"Jain T, Alahdab F, Firwana B, Sonbol MB, Almader-Douglas D, Palmer J. Choosing a reduced-intensity conditioning regimen for allogeneic stem cell transplantation, fludarabine\/busulfan versus fludarabine melphalan: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019; 25(4):728-733.","DOI":"10.1016\/j.bbmt.2018.11.016"},{"key":"54956","doi-asserted-by":"crossref","unstructured":"Jain T, Kunze KL, Temkit M. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2019; 54(2):204-211.","DOI":"10.1038\/s41409-018-0226-1"},{"key":"54957","doi-asserted-by":"crossref","unstructured":"McLornan D, Szydlo R, Koster L. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019; 25(11):2167-2171.","DOI":"10.1016\/j.bbmt.2019.06.034"},{"key":"54958","doi-asserted-by":"crossref","unstructured":"Robin M, Porcher R, Wolschke C. Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2016; 22(7):1206-1211.","DOI":"10.1016\/j.bbmt.2016.02.019"},{"key":"54959","doi-asserted-by":"crossref","unstructured":"Padron E, Garcia-Manero G, Patnaik MM. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015; 5(7):e333.","DOI":"10.1038\/bcj.2015.53"},{"key":"54960","doi-asserted-by":"crossref","unstructured":"Duchmann M, Yalniz FF, Sanna A. Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents. EBioMedicine. 2018; 31:174-181.","DOI":"10.1016\/j.ebiom.2018.04.018"},{"key":"54961","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Badbaran A, Beelen DW. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Adv. 2021; 5(6):1760-1769.","DOI":"10.1182\/bloodadvances.2020003600"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283426\/75810","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283426\/76319","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11143\/75810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:22Z","timestamp":1794045862000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283426","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}